高级检索
当前位置: 首页 > 详情页

Leonurine Attenuates Streptozotocin-Induced Diabetic Nephropathy in Rats by Mitigating Dyslipidemia and Inflammation

文献详情

资源类型:
WOS体系:

收录情况: ◇ SCIE

机构: [1]Hebei Univ, Dept Nephrol, Key Lab Skeletal Metab Physiol Chron Kidney Dis He, Affiliated Hosp, Baoding 071000, Peoples R China
出处:
ISSN:

关键词: Renal fibrosis Hyperglycemia Leonurine Insulin Dyslipidemia

摘要:
Background: Diabetic Nephropathy (DN) is one of the serious complications associated with a prolonged diabetic condition. DN continues to be the primary cause of morbidity and mortality among diabetic patients globally. Objectives: The objective of the current work is to study the nephroprotective properties of leonurine in the diabetic nephropathy model. Materials and Methods: The experimental rats were induced with DN through an administration of 65 mg/ kg of Streptozotocin (STZ) and the DN rats were treated with leonurine for 12 weeks. Following the treatment period, the blood glucose, insulin and glycosylated Hemoglobin (HbA1c) 1c ) levels were evaluated. The renal function markers, including creatinine, kidney injury molecule, ROS level, lipid profiles and pro-inflammatory cytokine levels, were examined using the kits. The renal tissues of the experimental rats were subjected to the histological studies. Results:The The outcomes of the present work found that the leonurine treatment considerably increased the insulin levels, decreased blood glucose and HbA1c 1c levels and decreased ROS production in the DN rats. In the DN rats, the treatment of leonurine significantly reduced the inflammatory markers, renal fibrotic markers, kidney dysfunction markers and lipid markers. The histological analysis results also confirmed leonurine's therapeutic effects against DN in rats. Conclusion: The current findings suggest that leonurine has the capacity to be a talented candidate to treat DN.

基金:
语种:
被引次数:
WOS:
中科院(CAS)分区:
出版当年[2025]版:
最新[2025]版:
大类 | 4 区 教育学
小类 | 4 区 学科教育 4 区 药学
JCR分区:
出版当年[2024]版:
最新[2023]版:
Q3 EDUCATION, SCIENTIFIC DISCIPLINES Q4 PHARMACOLOGY & PHARMACY

影响因子: 最新[2023版] 最新五年平均 出版当年[2024版] 出版当年五年平均 出版前一年[2023版]

第一作者:
第一作者机构: [1]Hebei Univ, Dept Nephrol, Key Lab Skeletal Metab Physiol Chron Kidney Dis He, Affiliated Hosp, Baoding 071000, Peoples R China
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:15679 今日访问量:0 总访问量:1035 更新日期:2025-06-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 河北大学附属医院 技术支持:重庆聚合科技有限公司 地址:保定市莲池区裕华东路212号